Are you looking to invest in a lucrative IPO that has the potential to generate significant returns? Look no further than the Suraksha Diagnostic IPO, which is set to open on November 29, 2024, and close on December 3, 2024. In this article, we’ll delve into the details of the Suraksha Diagnostic IPO, including its price band, market lot, and financial performance. Check our latest Quora blog on the similar topic.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 34 | ₹14,994 |
| Retail Maximum | 13 | 442 | ₹1,94,922 |
| S-HNI Minimum | 14 | 476 | ₹2,09,916 |
| S-HNI Maximum | 66 | 2,244 | ₹9,89,604 |
| B-HNI Minimum | 67 | 2,278 | ₹1,004,598 |
Suraksha Diagnostic IPO Details
The Suraksha Diagnostic IPO is a book-built issue that aims to raise approximately ₹846.25 crores. The IPO price band has been set at ₹420 to ₹441 per share, with a minimum market lot of 34 shares. The retail quota is 35%, while the QIB quota is 50% and the HNI quota is 15%.
| IPO Open Date: | November 29, 2024 |
|---|---|
| IPO Close Date: | December 3, 2024 |
| Face Value: | ₹2 Per Equity Share |
| IPO Price Band: | ₹420 to ₹441 Per Share |
| Issue Size: | Approx ₹846.25 Crores |
| Offer for Sale: | Approx 1,91,89,330 Equity Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
Suraksha Diagnostic IPO Financial Performance
Suraksha Diagnostic has reported impressive financial performance in recent years. The company’s revenue has grown from ₹190.13 crores in 2023 to ₹218.71 crores in 2024, representing a growth rate of 15%. The company’s profit after tax has also increased significantly, from ₹6.07 crores in 2023 to ₹23.13 crores in 2024.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
|---|---|---|---|---|
| 2022 | ₹223.19 | ₹197.76 | ₹20.82 | ₹275.96 |
| 2023 | ₹190.13 | ₹186.94 | ₹6.07 | ₹281.20 |
| 2024 | ₹218.71 | ₹190.03 | ₹23.13 | ₹300.21 |
Suraksha Diagnostic’s IPO Valuation
The Suraksha Diagnostic IPO valuation is attractive, with an EBITDA margin of 33.66% and a PAT margin of 10.57%. The company’s return on net worth (RoNW) is 14.09%, while its debt-to-equity ratio is 0.20.
| KPI | Values |
|---|---|
| ROE: | 14.09% |
| ROCE: | 21.46% |
| EBITDA Margin: | 33.66% |
| PAT Margin: | 10.57% |
| Debt to equity ratio: | 0.20 |
| Earning Per Share (EPS): | ₹4.43 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 14.09% |
| Net Asset Value (NAV): | ₹33.66 |
Suraksha Diagnostic’s IPO Peer Group Comparison
Suraksha Diagnostic’s financial performance is comparable to that of its peers in the diagnostic industry. The company’s EPS is ₹4.43, while its RoNW is 14.09%. In comparison, Dr. Lal PathLabs has an EPS of ₹43.05 and an RoNW of 20.35%, while Metropolis Healthcare has an EPS of ₹24.95 and an RoNW of 12.26%.
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
|---|---|---|---|---|---|
| Dr Lal PathLabs | 43.05 | 68.66 | 20.35 | 221.47 | 2226.60 Cr. |
| Metropolis Healthcare | 24.95 | 82.57 | 12.26 | 213.98 | 1207.71 Cr. |
| Thyrocare | 13.42 | 47.60 | 13.34 | 99.48 | 571.88 Cr. |
| Vijaya Diagnostic | 11.62 | 67.65 | 19.77 | 64.21 | 547.81 Cr. |
Conclusion
The Suraksha Diagnostic’s IPO is an attractive investment opportunity for those looking to invest in a leading diagnostic network in India. With its impressive financial performance, attractive valuation, and strong peer group comparison, this IPO has the potential to generate significant returns for investors.
Check recently listed NTPC Green and Enviro IPO’s listing news.